CN1852748A - 用作药物的氮杂䓬衍生物 - Google Patents

用作药物的氮杂䓬衍生物 Download PDF

Info

Publication number
CN1852748A
CN1852748A CNA2004800270768A CN200480027076A CN1852748A CN 1852748 A CN1852748 A CN 1852748A CN A2004800270768 A CNA2004800270768 A CN A2004800270768A CN 200480027076 A CN200480027076 A CN 200480027076A CN 1852748 A CN1852748 A CN 1852748A
Authority
CN
China
Prior art keywords
optionally substituted
heterocyclyl
alkyl
heteroaryl
ring
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2004800270768A
Other languages
English (en)
Chinese (zh)
Inventor
R·马丁
T·-L·王
B·T·弗拉特
X·-H·古
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Exelixis Inc
Original Assignee
Exelixis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Exelixis Inc filed Critical Exelixis Inc
Publication of CN1852748A publication Critical patent/CN1852748A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CNA2004800270768A 2003-07-23 2004-07-23 用作药物的氮杂䓬衍生物 Pending CN1852748A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US48985403P 2003-07-23 2003-07-23
US60/489,854 2003-07-23

Publications (1)

Publication Number Publication Date
CN1852748A true CN1852748A (zh) 2006-10-25

Family

ID=34102943

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2004800270768A Pending CN1852748A (zh) 2003-07-23 2004-07-23 用作药物的氮杂䓬衍生物

Country Status (14)

Country Link
US (1) US8466143B2 (enExample)
EP (1) EP1648408A4 (enExample)
JP (1) JP4679517B2 (enExample)
KR (1) KR20060052867A (enExample)
CN (1) CN1852748A (enExample)
AU (1) AU2004259009A1 (enExample)
BR (1) BRPI0412262A (enExample)
CA (1) CA2532798C (enExample)
CR (1) CR8258A (enExample)
EC (1) ECSP066392A (enExample)
IL (1) IL173287A0 (enExample)
NO (1) NO20060871L (enExample)
RU (1) RU2006105646A (enExample)
WO (1) WO2005009387A2 (enExample)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101875627A (zh) * 2009-04-30 2010-11-03 凯惠科技发展(上海)有限公司 一种1-烷氧羰基-2h-异吲哚衍生物及其制备方法和中间体
CN107207513A (zh) * 2014-11-21 2017-09-26 阿卡纳治疗学有限公司 用于治疗疾病的稠合双环化合物
CN107438612A (zh) * 2014-12-22 2017-12-05 阿卡纳治疗学有限公司 用于治疗疾病的稠合双环化合物
CN109789149A (zh) * 2016-05-25 2019-05-21 阿卡纳治疗学有限公司 用于治疗疾病的稠合双环化合物
CN109843298A (zh) * 2016-05-25 2019-06-04 阿卡纳治疗学有限公司 利用法尼酯x受体(fxr)调节剂的组合疗法
CN111542319A (zh) * 2017-06-02 2020-08-14 阿卡纳治疗学有限公司 稠合的双环化合物

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7595311B2 (en) * 2002-05-24 2009-09-29 Exelixis, Inc. Azepinoindole derivatives as pharmaceutical agents
US7402680B2 (en) 2003-09-17 2008-07-22 Janssen Pharmaceutica, N.V. Fused heterocyclic compounds
BRPI0608437A2 (pt) 2005-03-14 2009-12-29 Glaxo Group Ltd derivados tiazol fundidos que possuem afinidade para o receptor histamina h3
EP1963331A1 (en) * 2005-12-15 2008-09-03 Exelixis, Inc. Azepinoindole derivatives as pharmaceutical agents
US20080299118A1 (en) * 2007-06-01 2008-12-04 Wyeth FXR Agonists for the Treatment of Malignancies
US20080300235A1 (en) * 2007-06-01 2008-12-04 Wyeth FXR Agonists for Reducing LOX-1 Expression
US20090163474A1 (en) * 2007-10-19 2009-06-25 Wyeth FXR Agonists for the Treatment of Nonalcoholic Fatty Liver and Cholesterol Gallstone Diseases
US20090215748A1 (en) * 2007-12-20 2009-08-27 Wyeth FXR agonists for treating vitamin D associated diseases
BRPI0919948A2 (pt) 2008-10-31 2015-08-25 Madivation Technologies Inc Pirido[4,3-b]indois contendo porções rígidas
JP5551708B2 (ja) * 2008-10-31 2014-07-16 メディベイション テクノロジーズ， インコーポレイテッド アゼピノ［４，５−ｂ］インドール化合物およびその使用方法
EP2641907B1 (en) 2009-05-22 2015-01-28 AbbVie Inc. Preparation of modulators of 5-HT receptors
WO2011103433A1 (en) 2010-02-18 2011-08-25 Medivation Technologies, Inc. Pyrido[4,3-b]indole and pyrido[3,4-b]indole derivatives and methods of use
US9193728B2 (en) 2010-02-18 2015-11-24 Medivation Technologies, Inc. Fused tetracyclic pyrido [4,3-B] indole and pyrido [3,4-B] indole derivatives and methods of use
US9040519B2 (en) 2010-02-18 2015-05-26 Medivation Technologies, Inc. Fused tetracyclic pyrido [4,3-B] indole and pyrido [3,4-B] indole derivatives and methods of use
BR112012030534A2 (pt) * 2010-05-21 2015-09-29 Abbott Gmbh & Co Kg moduladores de receptores 5-ht e métodos de uso dos mesmos
WO2012112965A1 (en) * 2011-02-18 2012-08-23 Medivation Technologies, Inc. Compounds and methods of treating diabetes
EP2675459A4 (en) 2011-02-18 2014-08-06 Medivation Technologies Inc COMPOUNDS AND METHOD FOR THE TREATMENT OF DIABETES
WO2014031165A1 (en) * 2012-08-22 2014-02-27 Medivation Technologies, Inc. Compounds and methods of treating diabetes
TWI698430B (zh) * 2015-02-13 2020-07-11 南北兄弟藥業投資有限公司 三環化合物及其在藥物中的應用
HK1249756A1 (zh) * 2015-03-26 2018-11-09 Akarna Therapeutics, Ltd. 用於治疗疾病的稠合双环化合物
WO2017143134A1 (en) * 2016-02-19 2017-08-24 Alios Biopharma, Inc. Fxr modulators and methods of their use
CN112312909B (zh) 2018-01-26 2024-07-02 埃克塞里艾克西斯公司 用于治疗激酶依赖性病症的化合物
US11673897B2 (en) 2018-01-26 2023-06-13 Exelixis, Inc. Compounds for the treatment of kinase-dependent disorders

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GR35044B (el) * 1966-05-10 1968-07-31 The Upjohn Company Μεθοδος παρασκευης οργανικων ενωσεων.
US4362739A (en) * 1981-05-04 1982-12-07 S.A. Omnichem Pyrrolo(2,3-d)carbazole derivatives, compositions and use
IL101851A (en) * 1991-06-13 1996-05-14 Janssen Pharmaceutica Nv 10-(4-piperidinyl- and piperidinylidene)-imidazo [1,2-a] (pyrrolo thieno or furano) [2,3] azepine derivatives their preparation and pharmaceutical compositions containing them and certain novel intermediates therefor
JPH09221475A (ja) * 1996-02-13 1997-08-26 Yamanouchi Pharmaceut Co Ltd 新規なオキシム誘導体
WO1999006410A1 (en) * 1997-08-04 1999-02-11 Amgen Inc. Hydroxamic acid substituted fused heterocyclic metalloproteinase inhibitors
AR024576A1 (es) 1999-06-18 2002-10-16 Univ Washington Composiciones y metodos para aumentar el flujo de salida de colesterol y aumentar la hdl usando la proteina abc1 transportadora del cassette que une elatp
FR2796070B1 (fr) * 1999-07-06 2003-02-21 Lipha Derives de benzodiazepines utilisables dans le traitement de dyslipidemies, de l'atherosclerose et du diabete, compositions pharmaceutiques les contenant et procedes de preparation
MY122278A (en) * 1999-07-19 2006-04-29 Upjohn Co 1,2,3,4,5,6-hexahydroazepino[4,5-b]indoles containing arylsulfones at the 9-position
US20020013334A1 (en) * 2000-06-15 2002-01-31 Robl Jeffrey A. HMG-CoA reductase inhibitors and method
US7595311B2 (en) * 2002-05-24 2009-09-29 Exelixis, Inc. Azepinoindole derivatives as pharmaceutical agents
TWI329111B (en) 2002-05-24 2010-08-21 X Ceptor Therapeutics Inc Azepinoindole and pyridoindole derivatives as pharmaceutical agents
EP1963331A1 (en) * 2005-12-15 2008-09-03 Exelixis, Inc. Azepinoindole derivatives as pharmaceutical agents

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101875627A (zh) * 2009-04-30 2010-11-03 凯惠科技发展(上海)有限公司 一种1-烷氧羰基-2h-异吲哚衍生物及其制备方法和中间体
CN101875627B (zh) * 2009-04-30 2014-01-15 凯惠科技发展(上海)有限公司 一种1-烷氧羰基-2h-异吲哚衍生物及其制备方法和中间体
CN107207513A (zh) * 2014-11-21 2017-09-26 阿卡纳治疗学有限公司 用于治疗疾病的稠合双环化合物
CN107207513B (zh) * 2014-11-21 2020-07-28 阿卡纳治疗学有限公司 用于治疗疾病的稠合双环化合物
CN111662297A (zh) * 2014-11-21 2020-09-15 阿卡纳治疗学有限公司 用于治疗疾病的稠合双环化合物
CN107438612A (zh) * 2014-12-22 2017-12-05 阿卡纳治疗学有限公司 用于治疗疾病的稠合双环化合物
CN109789149A (zh) * 2016-05-25 2019-05-21 阿卡纳治疗学有限公司 用于治疗疾病的稠合双环化合物
CN109843298A (zh) * 2016-05-25 2019-06-04 阿卡纳治疗学有限公司 利用法尼酯x受体(fxr)调节剂的组合疗法
CN111542319A (zh) * 2017-06-02 2020-08-14 阿卡纳治疗学有限公司 稠合的双环化合物

Also Published As

Publication number Publication date
IL173287A0 (en) 2006-06-11
CR8258A (es) 2006-08-30
BRPI0412262A (pt) 2006-09-19
US20070015746A1 (en) 2007-01-18
RU2006105646A (ru) 2007-09-10
KR20060052867A (ko) 2006-05-19
ECSP066392A (enExample) 2007-01-26
JP4679517B2 (ja) 2011-04-27
EP1648408A1 (en) 2006-04-26
CA2532798A1 (en) 2005-02-03
US8466143B2 (en) 2013-06-18
WO2005009387A2 (en) 2005-02-03
CA2532798C (en) 2013-02-19
JP2006528637A (ja) 2006-12-21
EP1648408A4 (en) 2006-11-29
NO20060871L (no) 2006-04-24
AU2004259009A1 (en) 2005-02-03
WO2005009387A3 (en) 2006-03-02

Similar Documents

Publication Publication Date Title
CN1852748A (zh) 用作药物的氮杂䓬衍生物
CN1914207A (zh) 作为药物的氮杂䓬并吲哚衍生物
JP5420908B2 (ja) 医薬的薬剤としてのアゼピノインドール誘導体
CN1276790A (zh) 酰胺基噻唑衍生物及其制备方法与药物组合物
CN1204327A (zh) 药用活性喹唑啉类化合物
CN1177844C (zh) 作为cgrp拮抗剂的新环丙烷、包含该化合物的药物及其生产方法
CN1325390A (zh) 2－脲基噻唑衍生物及其制备方法和作为抗肿瘤剂的应用
CN1976907A (zh) 杂环酰胺化合物及其作为mmp－13抑制剂的用途
CN1106812A (zh) 三环二氮杂䓬加压素拮抗剂和催产素拮抗剂
CN1662508A (zh) 化合物、组合物和方法
CN1826334A (zh) 趋化因子受体活性的四氢吡喃基环戊基杂环酰胺调节剂
CN1849322A (zh) 噻吩并吡唑类化合物
US7902237B2 (en) Heterocyclic compounds as pharmaceutical agents
CN1531537A (zh) 用作保胎催产素受体拮抗剂的新型三环吡啶基苯并氮杂�羧酰胺及其衍生物
CN1771231A (zh) 钙受体调节性化合物及其用途
CN1812992A (zh) Hiv整合酶抑制剂
FR2927625A1 (fr) Nouveaux derives de 3-aminoalkyl-1,3-dihydro-2h-indol-2-one, leur preparation et leur application en therapeutique
CN1867562A (zh) 四唑衍生物和其代谢相关的疾病的治疗方法
EP2294068B1 (fr) DERIVES DE 1,3-DIHYDRO-2H-PYRROLO(3,2-b) PYRIDIN-2-ONE, LEUR PREPARATION ET LEURS APPLICATIONS EN THERAPEUTIQUE
CN1735618A (zh) 用作ltd4拮抗剂的新型三环衍生物
CN1286683A (zh) 四氢苯并吲哚衍生物
CN1726198A (zh) 化合物、组合物及方法
WO2020051707A1 (en) Indole-oxadiazole compounds and their therapeutic use
CN1758914A (zh) 用吲哚啉酮化合物治疗过度骨质溶解
MXPA06000875A (en) Azepine derivatives as pharmaceutical agents

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication